Chitinase 3-Like-1 [CPa9-HNE] and Vit-D levels in Crohn's Disease
Abstract
Background: Inflammatory Bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal tract, leading to various symptoms and complications, which includes conditions like Crohn's disease (CD)and ulcerative colitis (UC). These conditions are characterized by periods of active inflammation and remission, leading to a range of symptoms such as abdominal pain, diarrhea, weight loss, and fatigue. A defect in immune response, a product of environmental and genetic factors, are considered central cause to pathogenesis and etiology of IBD[1]
GP39 is a cartilage-specific protein associated with immune responses, predominantly expressed by activated T cells. Its involvement in the pathogenesis of IBD has been demonstrated through studies showing elevated levels of GP39 in the serum of IBD patients compared to healthy controls. Recently established that IBD associated with Vit-D deficiency.
Objectives: The study aimed to address the potential advantages of (HCgp39 and Vit-D ) as biomarkers for IBD and its medical treatment.
Methods: The total number of samples collected was 120 samples from all subjects, where 60 samples were collected from patients (D=30 and UC=30)) The study also included collecting 60 samples from healthy subjects as a control group. A (5 mL) blood sample was obtained from every patient as part of the study's protocol. Serum
was separated from by centrifugation for HCgp39 and Vitamin D3 analysis by ELISA.
Results: The results show a decrease in Vit-D3 was indicated in CD and UC patient groups (P ≤ 0.05), while HCgp38 levels were non-changed significantly in patient groups compared to control subjects, (P > 0.05).
Conclusions: In conclusion, the results suggests that serum decreased Vit- D correlated well with disease activity in both CD and UC. Targeting Vit-D3 could present a novel approach to regulate metabolic pathways and modulate immune responses, potentially providing new avenues for drug development and personalized treatment strategies for individuals with IBD
References
C. He et al., “View from the Biological Property: Insight into the Functional Diversity and Complexity of the Gut Mucus,” Int J Mol Sci, vol. 24, no. 4, p. 4227, 2023.
A. A. Almousa, M. Morris, S. Fowler, J. Jones, and J. Alcorn, “Elevation of serum pyruvate kinase M2 (PKM2) in IBD and its relationship to IBD indices,” Clin Biochem, vol. 53, pp. 19–24, 2018.
M. Henriksen et al., “C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study,” Gut, vol. 57, no. 11, pp. 1518–1523, 2008.
S. S. C. Ho, J. I. Keenan, and A. S. Day, “Urinary chitinase 3-like 1 and intestinal fatty-acid binding proteins are not elevated in children with inflammatory bowel disease,” Intest Res, vol. 20, no. 4, pp. 509–513, 2022.
J. Fletcher, S. C. Cooper, S. Ghosh, and M. Hewison, “The role of vitamin D in inflammatory bowel disease: mechanism to management,” Nutrients, vol. 11, no. 5, p. 1019, 2019.
J. Gubatan and A. C. Moss, “Vitamin D in inflammatory bowel disease: more than just a supplement,” Curr Opin Gastroenterol, vol. 34, no. 4, pp. 217–225, 2018.
S. Flynn and S. Eisenstein, “Inflammatory bowel disease presentation and diagnosis,” Surgical Clinics, vol. 99, no. 6, pp. 1051–1062, 2019.
G. G. Kaplan and J. W. Windsor, “The four epidemiological stages in the global evolution of inflammatory bowel disease,” Nat Rev Gastroenterol Hepatol, vol. 18, no. 1, pp. 56–66, 2021.
A. N. Ananthakrishnan, T. Donaldson, K. Lasch, and V. Yajnik, “Management of inflammatory bowel disease in the elderly patient: challenges and opportunities,” Inflamm Bowel Dis, vol. 23, no. 6, pp. 882–893, 2017.
S. Flynn and S. Eisenstein, “Inflammatory bowel disease presentation and diagnosis,” Surgical Clinics, vol. 99, no. 6, pp. 1051–1062, 2019.
E. Benvenuti, A. Pierini, E. Gori, C. Lucarelli, G. Lubas, and V. Marchetti, “Neutrophil-to-lymphocyte ratio (NLR) in canine inflammatory bowel disease (IBD),” Vet Sci, vol. 7, no. 3, p. 141, 2020.
B. O. Langley, S. E. Guedry, J. Z. Goldenberg, D. A. Hanes, J. A. Beardsley, and J. J. Ryan, “Inflammatory Bowel Disease and Neutrophil–Lymphocyte Ratio: A Systematic Scoping Review,” J Clin Med, vol. 10, no. 18, p. 4219, 2021.
S. Saraiva et al., “Evaluation of fatigue in inflammatory bowel disease-a useful tool in daily practice,” Scand J Gastroenterol, vol. 54, no. 4, pp. 465–470, 2019.
B. O. Langley, S. E. Guedry, J. Z. Goldenberg, D. A. Hanes, J. A. Beardsley, and J. J. Ryan, “Inflammatory Bowel Disease and Neutrophil–Lymphocyte Ratio: A Systematic Scoping Review,” J Clin Med, vol. 10, no. 18, p. 4219, 2021.
B. O. Langley, S. E. Guedry, J. Z. Goldenberg, D. A. Hanes, J. A. Beardsley, and J. J. Ryan, “Inflammatory Bowel Disease and Neutrophil–Lymphocyte Ratio: A Systematic Scoping Review,” J Clin Med, vol. 10, no. 18, p. 4219, 2021.
H. Chen, X. Wu, C. Xu, J. Lin, and Z. Liu, “Dichotomous roles of neutrophils in modulating pathogenic and repair processes of inflammatory bowel diseases,” Precis Clin Med, vol. 4, no. 4, pp. 246–257, 2021.
G. Wang et al., “Human umbilical cord mesenchymal stem cells alleviate inflammatory bowel disease by inhibiting ERK phosphorylation in neutrophils,” Inflammopharmacology, vol. 28, pp. 603–616, 2020.
M. Friedrich et al., “IL-1-driven stromal–neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies,” Nat Med, vol. 27, no. 11, pp. 1970–1981, 2021.
P. Giuffrida, G. R. Corazza, and A. Di Sabatino, “Old and new lymphocyte players in inflammatory bowel disease,” Dig Dis Sci, vol. 63, pp. 277–288, 2018.
A. Kaur and P. Goggolidou, “Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapies,” J Inflamm, vol. 17, pp. 1–8, 2020.
X. Zhang et al., “Blockade of IDO-kynurenine-AhR axis ameliorated colitis-associated colon cancer via inhibiting immune tolerance,” Cell Mol Gastroenterol Hepatol, vol. 12, no. 4, pp. 1179–1199, 2021.
A. Maoz, M. Dennis, and J. K. Greenson, “The Crohn’s-like lymphoid reaction to colorectal cancer-tertiary lymphoid structures with immunologic and potentially therapeutic relevance in colorectal cancer,” Front Immunol, vol. 10, p. 1884, 2019.
U. Roesler et al., “Identification of Chitinase-3-Like Protein 1 as a Novel Neutrophil Antigenic Target in Crohn’s,” J Crohns Colitis, vol. 894, p. 904, 2019.
T. Zhao, Z. Su, Y. Li, X. Zhang, and Q. You, “Chitinase-3 like-protein-1 function and its role in diseases,” Signal Transduct Target Ther, vol. 5, no. 1, p. 201, 2020.
C. Deutschmann et al., “Identification of chitinase-3-like protein 1 as a novel neutrophil antigenic target in Crohn’s disease,” J Crohns Colitis, vol. 13, no. 7, pp. 894–904, 2019.
P. Chen et al., “Serum biomarkers for inflammatory bowel disease,” Front Med (Lausanne), vol. 7, p. 123, 2020.
A. Jankowska-Konsur, Ł. Magdalena, K. Rubas, D. Nowicka-Suszko, M. A. J. Joanna, and J. C. Szepietowski, “Chitinase-3-like protein 1 (YKL-40): a new biomarker of inflammation in pyoderma gangrenosum,” Acta Derm Venereol, vol. 102, 2022.
S. S. C. Ho, J. I. Keenan, and A. S. Day, “Urinary chitinase 3-like 1 and intestinal fatty-acid binding proteins are not elevated in children with inflammatory bowel disease,” Intest Res, vol. 20, no. 4, pp. 509–513, 2022.
C. Douadi et al., “Anti-TNF agents restrict Adherent-invasive Escherichia coli replication within macrophages through modulation of Chitinase 3-like 1 in patients with Crohn’s disease,” J Crohns Colitis, vol. 16, no. 7, pp. 1140–1150, 2022.
A. G. Volkers et al., “Fecal Calprotectin, Chitinase 3-Like-1, S100A12 and Osteoprotegerin as Markers of Disease Activity in Children with Crohn’s Disease,” Gastrointestinal Disorders, vol. 4, no. 3, pp. 180–189, 2022.
J. Gubatan and A. C. Moss, “Vitamin D in inflammatory bowel disease: more than just a supplement,” Curr Opin Gastroenterol, vol. 34, no. 4, pp. 217–225, 2018.
J. Gubatan, N. D. Chou, O. H. Nielsen, and A. C. Moss, “Systematic review with meta‐analysis: association of vitamin D status with clinical outcomes in adult patients with inflammatory bowel disease,” Aliment Pharmacol Ther, vol. 50, no. 11–12, pp. 1146–1158, 2019.
J. H. White, “Vitamin D deficiency and the pathogenesis of Crohn’s disease,” J Steroid Biochem Mol Biol, vol. 175, pp. 23–28, 2018.
J. Lund-Nielsen, S. Vedel-Krogh, C. J. Kobylecki, J. Brynskov, S. Afzal, and B. G. Nordestgaard, “Vitamin D and inflammatory bowel disease: Mendelian randomization analyses in the Copenhagen studies and UK Biobank,” J Clin Endocrinol Metab, vol. 103, no. 9, pp. 3267–3277, 2018.
S.-A. Tabatabaeizadeh, N. Tafazoli, G. A. Ferns, A. Avan, and M. Ghayour-Mobarhan, “Vitamin D, the gut microbiome and inflammatory bowel disease,” J Res Med Sci, vol. 23, 2018.
S. O. Frigstad et al., “Vitamin D deficiency in inflammatory bowel disease: prevalence and predictors in a Norwegian outpatient population,” Scand J Gastroenterol, vol. 52, no. 1, pp. 100–106, 2017.
D. Caviezel, S. Maissen, J. H. Niess, C. Kiss, and P. Hruz, “High prevalence of vitamin D deficiency among patients with inflammatory bowel disease,” Inflamm Intest Dis, vol. 2, no. 4, pp. 200–210, 2018.
P. López-Muñoz, B. Beltrán, E. Sáez-González, A. Alba, P. Nos, and M. Iborra, “Influence of vitamin D deficiency on inflammatory markers and clinical disease activity in IBD patients,” Nutrients, vol. 11, no. 5, p. 1059, 2019.
